A Phase 1 interventional study of niacin (+) laropiprant and Comparator: aspirin in Primary Hypercholesterolemia and Mixed Hyperlipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc — 1 open to participants now, 1 under way, 1 of them phase 3. Hyperlipoproteinemia Type II · Merck & Co., Inc.
Among the 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc, this one is the 15th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 9th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →1 of the 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc is open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
By country, each count listing its studies:
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 13
First in 1985; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 381 across the 17 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
Drug: Comparator: aspirin · Drug: Comparator: clopidogrel · Drug: Comparator: laropiprant · Drug: Comparator: placebo
In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
Drug: Comparator: aspirin · Drug: Comparator: clopidogrel · Drug: Comparator: laropiprant · Drug: Comparator: placebo
Drug: niacin (+) laropiprant
open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
Also known as: Tredaptive
81 mg oral tablet once daily for 7 days
75 mg oral tablet once daily for 7 days
40 mg oral tablet once daily for 7 days
placebo oral tablet once daily for 7 days
Cutaneous Bleeding Time (BT)
Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days. The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable. Period 3 was not analyzed as bleeding time was not an objective for this part of the study.
Time frame: Day 8
| Milestone | All Participants |
|---|---|
| Started | 36 |
| Completed | 35 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | All Participants |
|---|---|
| Started | 35 |
| Completed | 34 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | All Participants |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days. The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable. Period 3 was not analyzed as bleeding time was not an objective for this part of the study.
| Seconds | Clopidogrel + Aspirin +Laropiprant | Clopidogrel + Aspirin |
|---|---|---|
| Cutaneous Bleeding Time (BT) | 478 (381 to 599) | 389 (309 to 490) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Laropiprant + Clopidrogel + Aspirin | — | 0/36 (0%) | 24/36 (66.7%) |
| Clopidogrel + Aspirin | — | 0/36 (0%) | 23/36 (63.9%) |
| Laropiprant + Niacin | — | 0/20 (0%) | 20/20 (100%) |
| Event | Laropiprant + Clopidrogel + Aspirin | Clopidogrel + Aspirin | Laropiprant + Niacin |
|---|---|---|---|
| VasodilationVascular disorders | 0/36 | 0/36 | 19/20 |
| HeadacheNervous system disorders | 5/36 | 4/36 | 4/20 |
| EcchymosisSkin and subcutaneous tissue disorders | 7/36 | 4/36 | 0/20 |
| Vessel puncture site haemorrhageGeneral disorders | 6/36 | 3/36 | 1/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/36 | 4/36 | 0/20 |
| NauseaGastrointestinal disorders | 0/36 | 1/36 | 2/20 |
| DizzinessNervous system disorders | 1/36 | 2/36 | 2/20 |
| Back painMusculoskeletal and connective tissue disorders | 3/36 | 2/36 | 0/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/36 | 1/36 | 0/20 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/36 | 3/36 | 0/20 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 55.0 (24 to 74) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 16 |
| Male | 20 |
No study locations are listed for this record.
The record gives a start of Nov 2009, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niacin · MK-0524 · Aspirin · Clopidogrel
Hyperlipoproteinemia Type II →